102074-24-8

Basic information

• Product Name: Pyridine, 3-ethoxy-, 1-oxide (6CI,9CI)
• Synonyms: Pyridine, 3-ethoxy-, 1-oxide (6CI,9CI)
• CAS NO: 102074-24-8
• Molecular Formula: C7H9NO2
• Molecular Weight: 139.15186
• Product Categories: PYRIDINE
• Mol File: 102074-24-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyridine, 3-ethoxy-, 1-oxide (6CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-ethoxy-, 1-oxide (6CI,9CI)(102074-24-8)
• EPA Substance Registry System: Pyridine, 3-ethoxy-, 1-oxide (6CI,9CI)(102074-24-8)

Safety Data

• Hazardous Substances Data: 102074-24-8(Hazardous Substances Data)

Upstream product

• 1851-22-5 3-chloropyridine-N-oxide 
• 141-52-6 sodium ethanolate 
• 14773-50-3 3-ethoxypyridine 
• 2311-91-3 monoperoxyphthalic acid 
• 626-60-8 3-Chloropyridine 
• 917-58-8 potassium ethoxide 
• 109-00-2 3-HYDROXYPYRIDINE 

Downstream Products

• 19349-73-6 3-ethoxy-4-nitropyridine-1-oxide 
• 14773-50-3 3-ethoxypyridine 

Relevant articles and documents

COMBINATIONS FOR TREATMENT OF NAFLD/NASH AND RELATED DISEASES

A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5- carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6- methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.

COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

Synthesis method of heterocyclic compound 3-methoxypyridine

The invention discloses a synthesis method of a heterocyclic compound 3-methoxypyridine. The method comprises the following steps: putting raw materials, i.e., 3-halogenated pyridine, hydrogen peroxide and acetic acid into a three-mouth flask, carrying out reaction for 4-8h at the temperature of 40-80 DEG C under the condition of stirring, recovering the acetic acid, adding a saturated sodium carbonate solution and stirring to enable a system to be alkaline, evaporating to remove water, then adding chloroform for washing, and carrying out vacuum distillation to obtain N-oxide-3-halogenated pyridine; respectively adding the N-oxide-3-halogenated pyridine, metal salt of alkyl alcohol, a catalyst A and alcohol into the three-mouth flask, carrying out reflux reaction for 5-8h under the condition of stirring, then cooling, neutralizing a product to be neutral, and carrying out distillation to obtain N-oxide-3-alkyloxypyridine; respectively adding the N-oxide-3-alkyloxypyridine, ferric trichloride, hydrazine hydrate, activated carbon and ethanol into the three-mouth flask, carrying out reaction at the temperature of 70 DEG C for 3h, cooling to room temperature, and carrying out vacuum distillation to obtain the 3-methoxypyridine. The synthesis method is high in intermediate conversion rate, mild in reaction conditions, safe in operation, low in price of raw materials and easy in raw material obtaining, thus being suitable for industrial production.